Stimulant vs Opioid Addiction Treatment: Side-by-Side Comparison (2026)

An evidence-based comparison to help you choose the right treatment approach. Data sourced from SAMHSA, NIDA, and published research.

RF
RehabFlow Editorial Team Updated: Apr 5, 2026

Quick Verdict

You have cocaine/methamphetamine dependence, behavioral interventions needed, no medication available.

You have heroin/fentanyl/prescription opioid dependence, MAT available, overdose prevention priority.

Not sure? Call (833) 567-5838 for a free clinical assessment.

Head-to-Head Comparison

FDA-Approved Medications
Stimulant Addiction Treatment
None (CM and behavioral therapy only)
Opioid Addiction Treatment
Three (methadone, buprenorphine, naltrexone)
Most Effective Treatment
Stimulant Addiction Treatment
Contingency management + CBT
Opioid Addiction Treatment
MAT + counseling
Withdrawal Type
Stimulant Addiction Treatment
Psychological (crash, depression, fatigue)
Opioid Addiction Treatment
Physical + psychological
Withdrawal Danger
Stimulant Addiction Treatment
Low physical risk, suicide risk elevated
Opioid Addiction Treatment
Uncomfortable but rarely fatal
Overdose Risk
Stimulant Addiction Treatment
Cardiac events, stroke, hyperthermia
Opioid Addiction Treatment
Respiratory depression (leading cause of death)
Treatment Duration
Stimulant Addiction Treatment
3-6 months intensive, then aftercare
Opioid Addiction Treatment
12+ months MAT (indefinite recommended)
Relapse Pattern
Stimulant Addiction Treatment
Binge-crash cycles common
Opioid Addiction Treatment
Gradual return or sudden relapse
Brain Recovery
Stimulant Addiction Treatment
Dopamine system: 12-18 months to normalize
Opioid Addiction Treatment
Opioid receptors: months to years
U.S. Annual Deaths
Stimulant Addiction Treatment
~33,000 (methamphetamine + cocaine)
Opioid Addiction Treatment
~80,000+ (opioids including fentanyl)
Treatment Gap
Stimulant Addiction Treatment
95% do not receive treatment
Opioid Addiction Treatment
80% do not receive treatment

Stimulant vs Opioid Addiction Treatment: Different Disorders, Different Approaches

Stimulant addiction (cocaine, methamphetamine) and opioid addiction require fundamentally different treatment strategies. The most critical distinction: opioid addiction has three FDA-approved medications that dramatically improve outcomes, while stimulant addiction currently has no approved medications, relying entirely on behavioral interventions.

The Medication Gap

This disparity is one of the biggest challenges in addiction medicine. Contingency management — rewarding clean drug tests with vouchers or prizes — has the largest effect sizes of any treatment for stimulant use disorder, according to NIDA. The VA system has implemented CM nationwide for stimulant addiction. Meanwhile, opioid addiction treatment without MAT has significantly worse outcomes — medication should be considered the standard of care.

Co-Occurring Stimulant and Opioid Use

Increasingly, people use both stimulants and opioids simultaneously or sequentially. Fentanyl-laced stimulants have made this combination especially deadly. Treatment for polysubstance use requires addressing both substance classes with integrated approaches. Call (833) 567-5838 to find programs experienced in treating co-occurring stimulant and opioid addiction.

Not Sure Which Is Right for You?

Our treatment specialists can assess your situation and recommend the right level of care. Free, confidential, 24/7.

(833) 567-5838

Frequently Asked Questions

Why are there no medications for stimulant addiction?
Unlike opioids, which act on a single receptor system, stimulants affect multiple neurotransmitter systems (dopamine, norepinephrine, serotonin), making pharmaceutical targeting more complex. Over 40 medications have been tested without achieving FDA approval. The most promising candidates include topiramate, mirtazapine, and injectable naltrexone, but none has shown consistent enough results in clinical trials.
What is contingency management for meth addiction?
Contingency management (CM) provides tangible incentives for verified abstinence — typically prize draws or vouchers for negative drug tests. NIDA meta-analyses show CM has the largest effect sizes of any psychosocial treatment for stimulant addiction. The VA has implemented a national CM program offering up to $599 in incentives over 12 weeks. Studies show CM doubles abstinence rates for methamphetamine users.
Is meth withdrawal dangerous?
Methamphetamine withdrawal is not physically dangerous like alcohol or benzodiazepine withdrawal, but it carries significant psychiatric risks. The withdrawal crash includes severe depression, anhedonia, hypersomnia, and increased appetite. Suicidal ideation is elevated during the first 1-2 weeks. Medical monitoring during initial withdrawal is recommended, particularly for mental health assessment and safety planning.
Can someone be addicted to both stimulants and opioids?
Yes, this is increasingly common and dangerous. Speedballing (combining cocaine with heroin) and using methamphetamine with fentanyl are high-risk patterns. Treatment must address both substances simultaneously. MAT for the opioid component combined with CM for the stimulant component represents the current best practice. Naloxone should be available given the opioid overdose risk.
How long does it take the brain to recover from meth?
Neuroimaging studies show significant dopamine system recovery occurs within 12-18 months of sustained abstinence from methamphetamine. Some cognitive functions (memory, attention, executive function) improve within weeks, while others take longer. Complete dopaminergic normalization may take several years. The good news is that the brain does recover substantially, which is a powerful motivator for sustained abstinence.

Last updated: April 5, 2026 • Sources: SAMHSA, NIDA, ASAM • RehabFlow Editorial Team

Home Find Centers Treatment Insurance Resources Compare Blog About